+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Proximus plc (PROX) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 43 Pages
  • July 2026
  • GlobalData
  • ID: 3500922
Proximus plc (PROX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Proximus plc (Proximus) is a provider of connectivity and digital services. The company is involved in the operation of open fixed and mobile networks, the development of digital ecosystems, and the provision of innovative solutions. Proximus offers a range of services, including fixed and mobile telephony, internet, and television services. The company provides services under several brands, such as Proximus, Scarlet, Mobile Vikings, Route Mobile, Telesign, BICS, Tango, and Doktr. It serves retail, industrial and commercial customers. The company has business presence in Luxembourg, France, Germany, the US, Singapore, Italy, Spain, the Netherlands and the UK. Proximus Group is headquartered in Brussels, Belgium.

Proximus plc Key Recent Developments

  • Jun 06, 2026: Proximus Activates Three 5G Slices at Red Devils Farewell Match

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • UCB SA - Key Facts
  • UCB SA - Key Employees
  • UCB SA - Key Employee Biographies
  • UCB SA - Major Products and Services
  • UCB SA - History
  • UCB SA - Company Statement
  • UCB SA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • UCB SA - Business Description
  • Product Category: Established Brands
  • Overview
  • Performance
  • Product Category: Immunology
  • Overview
  • Performance
  • Product Category: Neurology
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Target Markets
  • Performance
  • Geographical Segment: International Markets
  • Target Markets
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: U.S.
  • Performance
  • R&D Overview
  • UCB SA - Corporate Strategy
  • UCB SA - SWOT Analysis
  • SWOT Analysis - Overview
  • UCB SA - Strengths
  • UCB SA - Weaknesses
  • UCB SA - Opportunities
  • UCB SA - Threats
  • UCB SA - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • UCB SA, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jun 17, 2026: UCB Publishes Brain Communications Data Showing KYGEVVI Improves Outcomes in Patients With Thymidine Kinase 2 Deficiency (TK2d)
  • Jun 12, 2026: Reflections from EULAR 2026: advancing early control of inflammation
  • Jun 02, 2026: UCB Presents Research at Euromit 2026 Highlighting Burden of Care, Need for Earlier Diagnosis, and Impact of Pyrimidine Nucleoside Therapy on People Living With Tk2d
  • Jun 01, 2026: UCB Launches Scholarship Program for Adults With Hidradenitis Suppurativa and Immediate Family Members
  • May 21, 2026: FASTRAX Canada Expands to Québec City, Strengthening National Efforts to Accelerate AxSpA Diagnosis
  • May 07, 2026: UCB, Cancer Research UK and Cancer Research Horizons announce new strategic alliance to accelerate development of novel cancer therapies
  • May 07, 2026: UCB : Celebrating a decade of partnership advancing digital innovation in epilepsy care
  • Mar 25, 2026: UCB banks on Georgia for $2bn biologics manufacturing facility
  • Mar 24, 2026: UCB Selects Rowen for $2B Biopharmaceutical Manufacturing Campus
  • Feb 26, 2026: UCB Announces Full-Year Report 2025
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • UCB SA, Key Facts
  • UCB SA, Key Employees
  • UCB SA, Key Employee Biographies
  • UCB SA, Major Products and Services
  • UCB SA, History
  • UCB SA, Subsidiaries
  • UCB SA, Joint Venture
  • UCB SA, Key Competitors
  • UCB SA, Ratios based on current share price
  • UCB SA, Annual Ratios
  • UCB SA, Interim Ratios
  • UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • UCB SA, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • UCB SA, Performance Chart (2021 - 2025)
  • UCB SA, Ratio Charts
  • UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026